• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

BNT162b2 COVID-19 vaccine safe and efficacious in young children

byNhat Hung (Benjamin) LamandKiera Liblik
February 23, 2023
in Infectious Disease, Pediatrics, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A three-dose series of BNT162b2 was efficacious in eliciting an immune response and protecting children between six months and four years of age against coronavirus disease 2019 (COVID-19) infection.

2. The vaccine was evaluated to be safe with the majority of adverse events rated as mild to moderate.

Evidence Rating Level: 1 (Excellent)

Study Rundown: COVID-19 affects people of all ages, including young children. Although it is generally mild in this age group, severe disease leading to hospitalizations and multisystem inflammatory syndrome can still occur. Novel variants have also been associated with increased rates of hospitalization and transmissions. Existing mRNA-based vaccines, proven to be effective in preventing infection and severe disease, have not been adequately assessed in clinical trials in children younger than five years of age. The current study reported findings from a completed phase one and ongoing phase two/three trial to assess the safety, immunogenicity, and efficacy of the BNT162b2 vaccine in children between six months and four years of age. In contrast to the 30 microgram dose administered to older children and adults, these participants were given a three-dose series of 3 micrograms of BNT162b2. Overall, it was shown that BNT162b2 led to a strong antibody response as compared to a placebo. Correspondingly, the observed efficacy of BNT162b2 with respect to symptomatic COVID-19 was significantly increased. The safety profile was also favorable, with reactogenicity events being mainly mild to moderate, with none reaching severe. The incidence of fever was low across all age groups and comparable to the placebo. As a limitation, the trial was not powered to assess efficacy against severe disease or specific variants.

Click here to read the study in NEJM

Relevant Reading: Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

In-Depth [randomized controlled trial]: This study reported results from a phase one trial of the mRNA-based BNT162b2 COVID-19 vaccine among healthy children six months to four years of age. A total of 1,178 children six months to less than two years of age and 1,835 children two to four years of age were randomized in a 2:1 ratio to receive three doses of BNT162b2 or placebo. Immunogenicity outcome was assessed in participants without serologic or virologic evidence of previous SARS-CoV-2 infection and measured in neutralizing geometric mean titers (GMTs). Safety was assessed via reactogenicity events within seven days after each dose, adverse events, and severe events through to six months after the final dose. Geometric mean ratios of neutralizing GMTs elicited by three doses of BNT162b2 among children six months to less than two years of age and children two to four years of age relative to GMTs observed after dose two in individuals 16 to 25 years of age were 1.19 (95% Confidence Interval [CI], 1.00 to 1.42) and 1.30 (95% CI, 1.13 to 1.50), respectively. The observed efficacy of BNT162b2 against symptomatic COVID-19 across the entire participant pool was 73.2% (95% CI, 43.8 to 87.6), based on 34 recorded cases (13 in the BNT162b2 group and 21 in the placebo group). Lastly, BNT162b2 showed favorable safety outcomes, with the most common adverse events being local reactions, fever, irritability, and fatigue. Severe reactions and adverse events were infrequent; none reached grade four severity. In summary, these results demonstrated the safety and efficacy of a three-dose regimen of BNT162b2 for children between six months and four years of age for preventing COVID-19.

RELATED REPORTS

Mycobacterium abscessus infections after cardiac surgery linked to hospital water system

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bnt162b2BNT162b2 COVID-19 vaccineCOVID-19COVID-19 Vaccineinfectious diseasepediatricpublic healthpulmonology
Previous Post

RSV prefusion F protein vaccine is safe and effective in preventing RSV infection

Next Post

Use of questionnaires and tools to assess suicide risk in adolescents in the Emergency Department

RelatedReports

Standardized central line care practices reduce bloodstream infections
Infectious Disease

Mycobacterium abscessus infections after cardiac surgery linked to hospital water system

March 23, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]
Infectious Disease

Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus

March 20, 2023
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Chronic Disease

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

March 17, 2023
Next Post
Preterm birth associated with lower high school academic performance

Use of questionnaires and tools to assess suicide risk in adolescents in the Emergency Department

Sleep duration inversely related to childhood type 2 diabetes risk makers

Screen time and sedentary lifestyle associated with increased obesity rates among adolescents

Clinical practice guidelines linked to improved bronchiolitis outcomes

Ad26.RSV.preF-RSV vaccination prevents RSV infection in older adults

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
  • United States patients receive subcutaneous fluids less frequently than intravenous fluids when compared to Canadian patients
  • Spirituality, among many other factors, may help promote healthy ageing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options